Summit Therapeutics Inc.
NASDAQ Global MarketTotal Valuation
Summit Therapeutics Inc. carries a market capitalization of 10.67B, placing it among publicly traded companies globally. Its enterprise value stands at 10.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.67B |
| Enterprise Value | 10.28B |
Share Statistics
Summit Therapeutics Inc. currently has 776.02M shares outstanding.
| Shares Outstanding | 776.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -4.39 |
| P/TBV Ratio | 19.96 |
| P/FCF Ratio | -28.31 |
| P/OCF Ratio | -28.27 |
Financial Position
Summit Therapeutics Inc. maintains a current ratio of 7.41, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.41 |
| Quick Ratio | 7.19 |
| Debt / Equity | 3.67 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -233.81 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Summit Therapeutics Inc.'s stock has declined approximately -33.12257% over the past 52 weeks. The 50-day moving average sits at 18.09, while the 200-day moving average is 17.96.
| Beta (5Y) | N/A |
| 52-Week Price Change | -33.12257% |
| 50-Day Moving Average | 18.09 |
| 200-Day Moving Average | 17.96 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.22B, while operating income came in at -1.22B.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.22B |
| Pretax Income | -1.21B |
| Net Income | -1.21B |
| EBITDA | -1.22B |
| EBIT | -1.22B |
| Earnings Per Share (EPS) | -1.59 |
Balance Sheet
Summit Therapeutics Inc. holds 598.73M in cash and equivalents against 20.04M in total debt, resulting in a net debt position of -106.51M. Total book value stands at -2.48B, with working capital of 533.33M providing operational flexibility.
| Cash & Cash Equivalents | 598.73M |
| Total Debt | 20.04M |
| Net Debt | -106.51M |
| Equity (Book Value) | -2.48B |
| Book Value Per Share | -3.27 |
| Working Capital | 533.33M |
Cash Flow
Summit Therapeutics Inc. produced -384.05M in operating cash flow over the past twelve months. After subtracting -480,000.00 in capital expenditures, free cash flow totaled -384.53M - equivalent to -0.51 per share.
| Operating Cash Flow | -384.05M |
| Capital Expenditures | -480,000.00 |
| Free Cash Flow | -384.53M |
| FCF Per Share | -0.51 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.65 |
| FCF Yield | -3.53 |
Scores
Summit Therapeutics Inc. posts an Altman Z-Score of 53.28, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 53.28 |